Compound: Resiquimod
SMILES: O(Cc1nc2c(nc3c(c2n1CC(O)(C)C)cccc3)N)CC
InChIKey: BXNMTOQRYBFHNZ-UHFFFAOYSA-N
Synonyms: Resiquimod, 144875-48-9, 1-(4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol, R-848, R 848, 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol, S-28463, R848 compound, V3DMU7PVXF, R848, S 28463, CD11301, CD-11301, DTXSID7040603, CHEBI:36706, 4-Amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1H-Imidazo[4,5-c]quinoline-1-ethanol, 4-Amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol, resiquimodum, 1-(4-amino-2-(ethoxymethyl)-1H-imidazo(4,5-c)quinolin-1-yl)-2-methylpropan-2-ol, RefChem:178920, DTXCID5020603, 842-607-0, Resiquimod [INN], 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol, MFCD00937759, Resiquimod (GMP), 1H-Imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-, CHEMBL383322, R848;S28463, Resiquimod (R-848), 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methyl-propan-2-ol, UNII-V3DMU7PVXF, 1H-Imidazo(4,5-c)quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-, VML-600, ResiquimodR848?, RX8, R848; Resiquimod, RESIQUIMOD [MI], RESIQUIMOD [USAN], RESIQUIMOD [MART.], RESIQUIMOD [WHO-DD], SCHEMBL34159, MLS006010212, GTPL5051, orb1300307, Resiquimod, >=98% (HPLC), SCHEMBL29358122, BXNMTOQRYBFHNZ-UHFFFAOYSA-N, GLXC-06608, HMS3740O09, HMS5086I07, EX-A1879, BDBM50241029, HY-13740G, NSC828390, s8133, AKOS016003509, CCG-267635, CS-1706, DB06530, NSC-828390, SB17111, 1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol., 1-(4-Amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol, NCGC00370784-01, NCGC00370784-05, AC-35716, AS-30885, FR170507, HY-13740, SMR002530531, SY107476, CS-0645881, NS00071828, R0197, F223896, Q426054, SR-01000944954, SR-01000944954-1, alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol, BRD-K76210423-001-01-6, BRD-K76210423-001-02-4, 1H-Imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-|A,|A-dimethyl-, 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 4-amino-alpha,alpha-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-ethanol, 4-Amino-alpha,alpha-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol
Theoretical properties:
molecular_formula: C17H22N4O2
molecular_weight: 314.4 g/mol
exact_mass: 314.17427596 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 5
heavy_atom_count: 23
topological_polar_surface_area: 86.2 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Resiquimod is an imidazoquinoline.
chembl: RESIQUIMOD is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel in the treatment of skin lesions such as those caused by the herpes simplex virus and cutaneous T cell lymphoma, and as an adjuvant to increase the effectiveness of vaccines. In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8, and an upregulator of the opioid growth factor receptor.
On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma.